SOURCE: Novacea

October 31, 2006 20:00 ET

Novacea to Hold Conference Call Regarding Oral Vinorelbine Program

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- October 31, 2006 --

WHAT:

Novacea, Inc. (NASDAQ: NOVC) will hold a conference call to provide an update on the company's oral vinorelbine program. This conference call will be preceded by a news release at 8 a.m. Eastern Time (ET) on Wednesday, November 1. The conference call will be webcast live under the investor relations section of Novacea's website at www.novacea.com, and will be archived there for 7 days following the call. Please connect to Novacea's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

WHEN:

5:30 a.m. PT/8:30 a.m. ET, Wednesday, November 1, 2006

HOW:

Dial-in information:
Domestic: 866.356.3377
International: 1.617.597.5392
Participant code: 22435779

Replay:
Domestic: 888.286.8010
International: 1.617.801.6888
Passcode: 57441518
About Novacea

Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has three product candidates in clinical trials, including Asentar, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second product candidate, oral vinorelbine, is expected to enter a registration trial for metastatic breast cancer in the second half of 2006. Novacea's third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy.

Contact Information

  • Contacts:

    Nina Ferrari
    415.264.8796

    Paul Laland
    650.201.2688